| Margaret G Delposen I, MD | |
|
202 W Neshannock Ave, Hope Extended Care Services Inc, New Wilmington, PA 16142-1115 | |
| (724) 901-0003 | |
| (724) 946-2156 |
| Full Name | Margaret G Delposen I |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 202 W Neshannock Ave, New Wilmington, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386059889 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD062999L (Pennsylvania) | Primary |
| Entity Name | Nerve Pain Centers Of Western Pennsylvania |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114466349 PECOS PAC ID: 0345525523 Enrollment ID: O20170330002541 |
News Archive
A mixture of smaller countries led by New Zealand, Vietnam, Taiwan, Thailand, Cyprus, Rwanda and Iceland led the world 's Top 10 countries to manage their COVID-19 response well, according to a new study.
Sepsis is a major contributor to disability, death and health care costs in the United States and worldwide. A growing recognition of the high burden of sepsis as well as media coverage of high-profile, sepsis-induced deaths have catalyzed new efforts to prevent and manage the disease.
The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostics professionals, today announced the recipients of the Jeffrey A. Kant Leadership Award and the AMP Meritorious Service Award. Together with the AMP Award for Excellence in Molecular Diagnostics, these awards will be presented at the AMP 2016 Annual Meeting.
Tyrone Regional Health Network and Penn State Health have signed a letter of intent to enter into formal affiliation. With approval by organizational boards and state authorities, Tyrone Regional will become a member of Penn State Health.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Margaret G Delposen I, MD 202 W Neshannock Ave, Hope Extended Care Services Inc, New Wilmington, PA 16142-1115 Ph: (724) 901-0003 | Margaret G Delposen I, MD 202 W Neshannock Ave, Hope Extended Care Services Inc, New Wilmington, PA 16142-1115 Ph: (724) 901-0003 |
News Archive
A mixture of smaller countries led by New Zealand, Vietnam, Taiwan, Thailand, Cyprus, Rwanda and Iceland led the world 's Top 10 countries to manage their COVID-19 response well, according to a new study.
Sepsis is a major contributor to disability, death and health care costs in the United States and worldwide. A growing recognition of the high burden of sepsis as well as media coverage of high-profile, sepsis-induced deaths have catalyzed new efforts to prevent and manage the disease.
The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostics professionals, today announced the recipients of the Jeffrey A. Kant Leadership Award and the AMP Meritorious Service Award. Together with the AMP Award for Excellence in Molecular Diagnostics, these awards will be presented at the AMP 2016 Annual Meeting.
Tyrone Regional Health Network and Penn State Health have signed a letter of intent to enter into formal affiliation. With approval by organizational boards and state authorities, Tyrone Regional will become a member of Penn State Health.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
› Verified 3 days ago
Kelsey Dawn Puskar, PA-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 150 N New Castle St, New Wilmington, PA 16142 Phone: 724-946-3564 Fax: 724-946-2156 | |
Dr. James Larimer Gardner Iii, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 150 N New Castle St, New Wilmington, PA 16142 Phone: 724-946-3564 Fax: 724-946-2156 | |
Dr. Anthony Frederick Uberti, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3438 State Route 208, New Wilmington, PA 16142 Phone: 724-946-8979 Fax: 724-946-2938 | |
Amanda Carl, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 150 N New Castle St, New Wilmington, PA 16142 Phone: 724-946-3564 Fax: 724-946-2156 | |
Kary Schroyer, Family Medicine Medicare: Medicare Enrolled Practice Location: 3438 State Route 208, New Wilmington, PA 16142 Phone: 724-946-8979 |